NEAT1 is a therapeutic target for reversing T-cell exhaustion in bladder cancer

lncRNA NEAT1 serves as a modulator of the antitumor response of CD8+T cells in the bladder tumor microenvironment and may represent a therapeutic target for reversing T-cell exhaustion.

Authors

Institutions

Publication Details

Journal
Journal for ImmunoTherapy of Cancer
Published
2025-12-01
DOI
https://doi.org/10.1136/jitc-2025-013733
Citations
1
Primary Topic
Cancer-related molecular mechanisms research
Type
article
Field-Weighted Citation Impact
0.94

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

NEAT1 is a therapeutic target for reversing T-cell exhaustion in bladder cancer

Jinxiang Han, Lixin Niu, Kun Li, Ziqiang Wang et al.
1 citations
Journal for ImmunoTherapy of Cancer
Cancer-related molecular mechanisms research
0.94
article

NEAT1 is a therapeutic target for reversing T-cell exhaustion in bladder cancer

Jinxiang Han, Lixin Niu, Kun Li, Ziqiang Wang, Lin Wang, Xiaoyan Zhou, Xufei Zhang, Tianzi Li
article en
1 citations

Abstract

lncRNA NEAT1 serves as a modulator of the antitumor response of CD8+T cells in the bladder tumor microenvironment and may represent a therapeutic target for reversing T-cell exhaustion.

Journal for ImmunoTherapy of CancerVol. 13(12)
Shandong Provincial Hospital (CN), First Affiliated Hospital of Jinan University (CN), Shandong First Medical University (CN)
Natural Science Foundation of Shandong Province
Openalex Percentile: Top 18%
Cancer-related molecular mechanisms research
0.94
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.